Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkOlaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

From JAMA Network Open comes this conclusion: “In this study, the benefit associated with olaparib was reduced, eliminated, or inferior in specific subgroups of patients when treatment outcomes were compared with a more active standard of care, ie, cabazitaxel. While treatment with olaparib was associated with superior rPFS in patients with BRCA1/2 variants, those with other HRR variants may have worse outcomes with this approach, which should be reassessed by national guidelines. Numerous active studies…will add to the data regarding the role of PARP inhibitors in mCRPC.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form